CN101125167A - Medicine for treating influenza - Google Patents

Medicine for treating influenza Download PDF

Info

Publication number
CN101125167A
CN101125167A CNA2006101069086A CN200610106908A CN101125167A CN 101125167 A CN101125167 A CN 101125167A CN A2006101069086 A CNA2006101069086 A CN A2006101069086A CN 200610106908 A CN200610106908 A CN 200610106908A CN 101125167 A CN101125167 A CN 101125167A
Authority
CN
China
Prior art keywords
radix
present
medicine
rhizoma
root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006101069086A
Other languages
Chinese (zh)
Inventor
王玉怀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNA2006101069086A priority Critical patent/CN101125167A/en
Publication of CN101125167A publication Critical patent/CN101125167A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a drug for treating influenza, which includes: Chinese thorowax root, baical skullcap root, incised notopterygium rhizome, divaricate saposhnikovia root, rhubarb, immature bitter orange, golden thread, amur corktree bark, pinellia tuber, figwort root, Indian buead and oriental waterplantain rhizome. By adopting the pure traditional Chinese medicines, the drug for treating influenza provided by the present invention can greatly reduce the sufferings of the patients during the treatment process, furthermore, the present invention can avoid the toxicity and side effects generated by penicillin and other antibiotic drugs on the patients; as the price of the traditional Chinese medicine components is relatively lower than western medicine, the present invention further reduces the treatment cost.

Description

The medicine of treatment influenza
Technical field
The present invention relates to a kind of medicine, especially a kind of Chinese medicine for the treatment of influenza belongs to field of traditional Chinese.
Background technology
The main antibiotics such as penicillin of present existing treatment influenza with doctor trained in Western medicine, but the patient has complication in therapeutic process, increases patient's misery, and face SARS, bird flu that new variant viral bacterial strain causes, just feel simply helpless.
Summary of the invention
The purpose of this invention is to provide a kind of medicine for the treatment of influenza,, and avoid the patient is produced toxic and side effects, reduce the treatment cost simultaneously with the misery of reduction patient in therapeutic process.
For achieving the above object, the invention provides a kind of medicine for the treatment of influenza, comprising: Radix Bupleuri, Radix Scutellariae, river Qiang, Radix Saposhnikoviae, Radix Et Rhizoma Rhei, Fructus Aurantii Immaturus, Rhizoma Coptidis, Cortex Phellodendri, the Rhizoma Pinelliae, Radix Scrophulariae, Poria, Rhizoma Alismatis.
Wherein the shared ratio in medicine of each Chinese medicine ingredients can be Radix Bupleuri 13%-15%, Radix Scutellariae 11%-13%, the 5%-6% of river Qiang, Radix Saposhnikoviae 5%-6%, Radix Et Rhizoma Rhei 9%-10%, Fructus Aurantii Immaturus 7%-9%, Rhizoma Coptidis 5%-6%, Cortex Phellodendri 5%-6%, Rhizoma Pinelliae 7%-9%, Radix Scrophulariae 7%-9%, Poria 9%-10%, Rhizoma Alismatis 9%-10%.
Medicine by treatment influenza provided by the invention, owing to adopt pure Chinese medicine to make fully, greatly reduce the misery of patient in therapeutic process, and the toxic and side effects of having avoided antibiotics such as penicillin that the patient is produced, because the relative Western medicine of price of Chinese medicinal components is cheap, has also further reduced the treatment cost.
Below by embodiment, technical scheme of the present invention is described in further detail.
The specific embodiment
The medicine of treatment influenza of the present invention comprises: Chinese medicines such as Radix Bupleuri, Radix Scutellariae, river Qiang, Radix Saposhnikoviae, Radix Et Rhizoma Rhei, Fructus Aurantii Immaturus, Rhizoma Coptidis, Cortex Phellodendri, the Rhizoma Pinelliae, Radix Scrophulariae, Poria, Rhizoma Alismatis, and its pharmacology is as follows: Radix Bupleuri, Radix Scutellariae, river Qiang have immune stimulating and phagocytic function; With Radix Et Rhizoma Rhei, Fructus Aurantii Immaturus dispelling pathogen in the interior catharsis, the diuresis of can purging heat of Cortex Phellodendri, Poria, Rhizoma Alismatis makes virus be excreted by defecation, to reach the effect of " removing burning wood away under the boiler "; The blood oxygen supply that Radix Et Rhizoma Rhei energy microcirculation improvement, increase are organized promotes growth, propagation, differentiation, maturation and the release of pluripotent stem cell, so the rapid disease controlling of energy is cured influenza.
Medicine of the present invention can adopt following ratio to be configured: Radix Bupleuri 13%-15%, Radix Scutellariae 11%-13%, the 5%-6% of river Qiang, Radix Saposhnikoviae 5%-6%, Radix Et Rhizoma Rhei 9%-10%, Fructus Aurantii Immaturus 7%-9%, Rhizoma Coptidis 5%-6%, Cortex Phellodendri 5%-6%, Rhizoma Pinelliae 7%-9%, Radix Scrophulariae 7%-9%, Poria 9%-10%, Rhizoma Alismatis 9%-10%.
Adopt Chinese medicine of the present invention, the cost of treatment influenza is reduced, do not have complication, alleviate the patient suffering, have no side effect.Clinical Practice 213 illustrations are bright: with the influenza that the various virus of this side's treatment causes, effective percentage 100%, cure rate is more than 98%.
Provide the embodiment of a concrete prescription below: choose Radix Bupleuri 10-15 gram, Radix Scutellariae 10-12 gram, the 3-6 of river Qiang gram, Radix Saposhnikoviae 3-6 gram, Radix Et Rhizoma Rhei 6-10 gram, Fructus Aurantii Immaturus 5-10 gram, Rhizoma Coptidis 3-6 gram, Cortex Phellodendri 3-6 gram, Rhizoma Pinelliae 6-8 gram, Radix Scrophulariae 5-10 gram, Poria 6-10 gram, Rhizoma Alismatis 6-10 gram, more than each medicine join by measuring, add the 1000ml decocting and endure to 500ml and get final product, oral.
In addition, prescription of the present invention also can pass through commercial run, is made into other forms such as tablet, electuary.
It should be noted that at last: above embodiment is only in order to technical scheme of the present invention to be described but not limit it, although the present invention is had been described in detail with reference to preferred embodiment, those of ordinary skill in the art is to be understood that: it still can make amendment or be equal to replacement technical scheme of the present invention, and these modifications or be equal to replacement and also can not make amended technical scheme break away from the spirit and scope of technical solution of the present invention.

Claims (3)

1. a medicine for the treatment of influenza is characterized in that comprising Radix Bupleuri, Radix Scutellariae, river Qiang, Radix Saposhnikoviae, Radix Et Rhizoma Rhei, Fructus Aurantii Immaturus, Rhizoma Coptidis, Cortex Phellodendri, the Rhizoma Pinelliae, Radix Scrophulariae, Poria, Rhizoma Alismatis.
2. according to the described medicine of claim 1, it is characterized in that the content of each each composition of Chinese medicine is: Radix Bupleuri 13%-15%, Radix Scutellariae 11%-13%, the 5%-6% of river Qiang, Radix Saposhnikoviae 5%-6%, Radix Et Rhizoma Rhei 9%-10%, Fructus Aurantii Immaturus 7%-9%, Rhizoma Coptidis 5%-6%, Cortex Phellodendri 5%-6%, Rhizoma Pinelliae 7%-9%, Radix Scrophulariae 7%-9%, Poria 9%-10%, Rhizoma Alismatis 9%-10%.
3. medicine according to claim 1 is tablet or electuary.
CNA2006101069086A 2006-08-17 2006-08-17 Medicine for treating influenza Pending CN101125167A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA2006101069086A CN101125167A (en) 2006-08-17 2006-08-17 Medicine for treating influenza

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2006101069086A CN101125167A (en) 2006-08-17 2006-08-17 Medicine for treating influenza

Publications (1)

Publication Number Publication Date
CN101125167A true CN101125167A (en) 2008-02-20

Family

ID=39093359

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006101069086A Pending CN101125167A (en) 2006-08-17 2006-08-17 Medicine for treating influenza

Country Status (1)

Country Link
CN (1) CN101125167A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103202868A (en) * 2013-04-02 2013-07-17 西北农林科技大学 Composition for preventing and treating flu as well as preparation method and application thereof
CN104940760A (en) * 2015-06-10 2015-09-30 青州市食用菌研究所 Four compositions for preventing and treating acute epidemic disease and preparation processes thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103202868A (en) * 2013-04-02 2013-07-17 西北农林科技大学 Composition for preventing and treating flu as well as preparation method and application thereof
CN103202868B (en) * 2013-04-02 2014-11-26 西北农林科技大学 Composition for preventing and treating flu as well as preparation method and application thereof
CN104940760A (en) * 2015-06-10 2015-09-30 青州市食用菌研究所 Four compositions for preventing and treating acute epidemic disease and preparation processes thereof

Similar Documents

Publication Publication Date Title
CN102512630B (en) Traditional Chinese medicine composition for treating gallbladder calculus
CN1390585A (en) Chinese medicine for detoxication purpose and its preparing process
CN101491614B (en) Traditional Chinese medicine composition for treating mouth and tongue sore and stomatocace
CN101905006A (en) External medicament for treating traumatic injury
CN102078524A (en) Chinese traditional medicine composition for treating pharyngitis
CN101125167A (en) Medicine for treating influenza
CN101810788A (en) Chinese medicinal preparation for curing cystitis
CN101884663A (en) Traditional Chinese medicine for treating cold and parotitis
CN100579544C (en) Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof
CN1041495C (en) External application medicine for curing hepatic disease
CN104623379B (en) A kind of pharmaceutical composition for the treatment of Hand-Food-Mouth Disease
CN102380038A (en) Medicine for treating scrofula and red-hot needle therapy
CN1292275A (en) Chinese medicine preparation for curing postpartum disease of woman
CN100398143C (en) Medicament for treating vitiligo
CN1257732C (en) Medicine for treating mastosis and preparation process thereof
CN1170559C (en) Capsule for removing heat from liver and detoxicating and its preparing process
CN1060374C (en) Ointment for treating hemorrhoid
CN1075726C (en) Oral liquid for treatment of heart disease and its prepn. method
CN1201769C (en) Medicine for treating diabetes, nephropathy
CN106552134A (en) A kind of Chinese medicinal formulae for treating periodontal disease
CN1148201C (en) Preparing method for auxiliary feedback treatment of disease medicine
CN101744963A (en) Traditional Chinese medicine preparation for detumescence by detoxification
CN101168039A (en) Traditional Chinese medicine for treating ascariasis
CN100998757A (en) Medicine for relieving pain and strengthening teeth
CN103028098A (en) Preparation method of traditional Chinese medicine prescription for treating ulcerative colitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080220